# E-DRUG: New Drug Classes on Formularies (cont) **URL:** \ **Category:** e-drug\ **Created:** [November 10, 1999, 8:47pm UTC](https://talk.edrugplus.org/t/e-drug-new-drug-classes-on-formularies-cont/6586 "1999-11-10T20:47:26Z")\ **Posts on this page:** 1\ **Page:** 1
**Author:** ![Lynn\_Weekes](https://avatars.discourse-cdn.com/v4/letter/l/e480ec/32.png) [@Lynn\_Weekes](https://talk.edrugplus.org/u/Lynn_Weekes)\ **Post date:** [November 10, 1999, 8:47pm UTC](https://talk.edrugplus.org/t/e-drug-new-drug-classes-on-formularies-cont/6586/1 "1999-11-10T20:47:26Z")
E-drug: New Drug Classes on Formularies (cont) --------------------------------------------- Dear all The body of literature is quite limited. The indicators for drug and therapeutics committees in Australia recommend use of following information: Balanced, comparative (against placebo and/or usual therapy) information on safety and efficacy Assessment of clinical need Economic analysis The most commonly used pieces of information to make a formulary decision by DTCs are: BY efficacy - 83% side effects - 71% whether an alternative is available - 87% indication - 64% sponsor (clinician making the request) - 59% estimated usage - 78% drug cost - 80% drug budget - 55% cost-effectiveness - 67% Scenario-based work confirmed the principle information used and showed that the process involved significant consultation and discussion prior to the meeting. There is also some work published by Bochner F et al in the BMJ on a prioritisation model for formulary addition. This is a controversial approach but interesting. regards Lynn Weekes National Prescribing Service 9 Leichhardt St, Darlinghurst 2010 Tel 61 2 9332 3944 Mob 0413 834 438 Fax 61 2 9332 3955 "Lynn Weekes" \ -- Send mail for the `E-Drug' conference to `e-drug@usa.healthnet.org'. Mail administrative requests to `majordomo@usa.healthnet.org'. For additional assistance, send mail to: `owner-e-drug@usa.healthnet.org'.